Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
5(45%)
Results Posted
0%(0 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
6
55%
Ph phase_1
2
18%
Ph phase_2
1
9%
Ph phase_4
1
9%
Ph early_phase_1
1
9%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
6(54.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(7)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting5
Not yet recruiting2
Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (9.1%)
Phase 12 (18.2%)
Phase 21 (9.1%)
Phase 41 (9.1%)
N/A6 (54.5%)

Trials by Status

not_yet_recruiting218%
recruiting545%
unknown19%
terminated19%
completed218%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials

All 11 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
11